ISSN: 2373-6367PPIJ

Pharmacy & Pharmacology International Journal
Research Article
Volume 2 Issue 5 - 2015
Somina (Herbal Preparation): Partial Muscarinic Agonist
Muhammad Ahmed1* and Aisha Azmat2
1Department of Pharmacology, Saudi Arabia
2Department of Physiology, Saudi Arabia
Received: May 29, 2015 | Published: July 25, 2015
*Corresponding author: Muhammad Ahmed, Department of Pharmacology, Faculty of Pharmacy, Umm-Al-Qura University, Makkah, Saudi Arabia, Tel: 00966-025270000 ext 4282, 00966-556618257; Email:
Citation: Ahmed M , Azmat A (2015) Somina (Herbal Preparation): Partial Muscarinic Agonist. Pharm Pharmacol Int J 2(5): 00033. DOI: 10.15406/ppij.2015.02.00033


Purpose: To evaluate the agonistic property of somina (herbal drug) on muscarinic receptor.
Methods: For determination of effect of somina on receptor rabbit heart was in the Langendorff apparatus coupled with four channels Harvard Universal Oscillograph. The heart was perfused with different solutions like; Somina (20mg/ml), Ach 10-3, Atr 10-3+ somina, Atr 10-3+ Ach 10-3 and Somina (20mg/ml) +Ach 10-3 and effect on heart rate was recorded. The records were used for the calculations of heart rate (beat per min).
Results: Somina and Ach 10-3 caused significant (p < 0.05) reduction in heart rate (28% and 52% respectively) however non significant reduction in heart rate was observed (3 and 11 %, p > 0.05) after atropine treatment. Receptor activity confirms that Somina act on Ach receptors. 33% reduction in heart rate was observed after perfusion with Somina (20mg/ml) +Ach 10-3. Somina competing with Ach 10-3 (the full agonist) for the same muscarinic receptor and thereby reducing the ability of the full agonist to produce its maximum effect (Ach 10-3 52%; Somina+Ach10-3 37% reduction) when both full agonist (Ach) administered simultaneously with somina.
Conclusion: Somina is a partial agonist at non-selective muscarinic receptors.

Keywords:  Somina; Herbal preparation; Heart rate; Muscarinic receptor; Partial agonist


Many herbal formulated preparations are used in folk medicine as remedies for the treatment of a variety of human ailments from time immemorial. One of the traditional medicine “Somina” is one of the traditional medicine, formulated by Hamdard laboratories (Waqf) Pakistan. It is claimed that Somina is a cephalic tonic having sedative, hypnotic and anxiolytic activities. It is also claimed that somina is effective in weakness of brain and memory. Previously researcher has suggested that somina affect brain serotonin levels and enhances the memory. Five Medicinal plants in different ratio are present in Somina. Sesamum indicum (14%), Lagenaria vulgaris (12%), Prunus amygdalus (12%), Papaver somniferum (10%)and Lactuca scariola (5%). These medicinal plants not only affect the brain activity but affect the cardiac activity like Sesamum indicum (14%) prevent the high blood pressure [1], Prunus amygdalus (12%) decrease the coronary heart disease risk [2], Papaver somniferum (10%)protect against heart attacks[3], Lactuca scariola (5%)is a vasorelaxant [4]and Lagenaria vulgaris (12%) worked as cardio-protective [5]. Previous studies suggest that somina stimulates the muscarinic receptor and reduced the heart rate and mean arterial Blood Pressure. In the light of previous reported data it was concluded the somina is a muscarinic receptor agonist. Now-a-days, common drugs have been classified according to their receptor activity like buspirone, aripiprazole and buprenorphine classified as partial agonists [6]. However, still it is not confirmed that somina is a full agonist or partial agonist that’s why the present study was planned to further confirm the agonistic property of somina on rabbit isolated heart preparation.

The approach to modulation of CNS peptide pathways could be promising. Investigators looking for safe and effective ways to inhibit hunger, increase satiety without followed adverse effects. Some interesting results obtained from research of NPY antagonists [19,20], melanin concentrating hormone (MSH) receptor antagonists [21] and melanocyte stimulants lately [20]. As an example,ARC NPY neurons mediate hyperphagia and obesity in the ob/ob and db/db mice and fa/fa rat, in which leptin inhibition is lost through mutations affecting leptin or its receptor. Antagonists of the Y5 receptor (currently thought to be the NPY 'feeding' receptor) have anti-obesity effects [20]. Some authors do discuss the effectiveness of NPYY5 receptors inhibition, as a possible anti-obesity treatment approach [19]. The treatment with the MCH1 receptor antagonist at 30 (-1) for 1 month moderatelysuppressed feeding and significantly reduced body weight by 24% in a rodent model [21]. Other pathway in obesity treatment research is the investigation of adipose tissue and gut hormones as PYY3-36 [22], oxyntomodulin [9] [23], ghrelin [23], leptin and GLP-1RA [23]. Evidently, administration of PYY(3-36) resulted in increased ratings of satiety and decreased ratings of hunger, thirst, and prospective food consumption [22]. Gut hormones acutely modulated the peptidergic pathways, resulting in a stimulation hunger effects by ghreline, or in an inhibition effects by PYY and oxintomoduline [23].

Materials and Methods

Herbal preparations (Somina)

A patent formulation of Hamdard laboratories, Waqf. Pakistan (Somina) was obtained in the form of crumb/powder. 20mg/ml dose of somina were used in this experiment as this dose was said to be maximum effective dose. Somina (20mg/ml) were freshly prepared by dissolving somina in warm distilled water for experimental use.

Kreb’s Henseleit buffer solution: Kreb’s Henseleit Buffer solution was used for perfusion. The composition of solution was 118mM; NaCl, 4.70 mM; KCl, 1.25 mM; CaCl2, 1.20 mM; MgSO4, 25 mM; NaHCO3 & 11 mM Glucose. All chemicals were obtained from E-Merck, Germany.

Animals: Rabbits (Oryctolagus cunniculus) of either sexranging from 1.0-2.0 Kg were used for experiments. The Standing Research Committee on Animal Research and Ethics from our institution approved the animal handling protocol.

Experimental procedure
These experimental animals were killed by decapitation and heart was isolated with intact aorta immediately and mounted in the Langendorff apparatus coupled with four channels Harvard Universal Oscillograph. The heart was perfused at a constant pressure retrogradely with filtered Krebs-Henseleit solution saturated with 95% O2+5% CO2 and regulated at 37°C. Ventricular activity of heart was recorded through isotonic transducer on Oscillograph. After the stabilization of the heart, it was then perfused with different solutions like; Somina (20mg/ml), Ach 10-3 for comparison, Atr 10-3+ somina, Atr 10-3+ Ach 10-3 for receptor activity and Somina (20mg/ml) +Ach 10-3 for agonist activity on different animals. Care was taken to administer a single dose for at least 3 to 5 minutes before taking records of heart activity. After recording, the heart was washed with normal solution for 10-15 min, before the same/second dose was tested for next observation. For every observation, the activity recorded before administration of any dose was considered as control. A total of 15 rabbits were used in the present study. The records were used for the calculations of heart rate (beat per min).

Statistical analysis

All the data was normalized to percent of control. And the standard statistical tools, i.e., mean and Standard Errors were determined for its analysis.


Somina (20mg/ml) produced a negative chronotropic effect on heart as compared to its control. The reduction in heart rate (negative chronotropic effect) was 28% as compare to their controls (Table 1). While, after Atr (10-3 M) pretreatment, 20mg/ml Somina was found to decrease the heart rate non significantly (p>0.05). This reduction was 3% than its control (Table 1). Ach 10-3 had demonstrated a decrease in heart rate that was 52% than its respective control. Further, in Atr (10-3) pre-treated heart, the Ach (10-3) did not show such decline in heart rate as shown earlier. The reduction in heart rate is decline with Atr (10-3) pre-treatment was only 11% than its control. Single treatment of somina cause 28% and Ach 10-3 caused 52% reduction. For the determination of agonist activity both were administered at the same time cause a total 37% reduction in heart rate (Table 1).

Figure 1: Proposed Graphical illustration indicating the Action of Full (Ach) and Partial (Somina) Agonist with muscarinic receptors.

S. No


Reduction in Heart Rate Mean + S.E. (n)


Somina (20mg/ml)

28.03+0.08 (30)


Ach (10-3)

52.41+1.67 (30)


Atr 10-3+Somina (20mg/ml)

03.43+1.02 (30)


Atr 10-3+Ach (10-3)

11.06+2.35 (30)


Somina 20mg/ml + Ach (10-3)

36.95+0.14 (30)

Table 1: Effect of Somina (20mg/ml) and various treatments on Heart rate (beats/min).

The values has been presented as percent of control


Literature reviews indicate that medicinal plant that is the constituent of somina possesses cardiac activity. Previous study on intact frog heart concluded that Somina (20mg/ml) is an active herbal medicine that affects cholinergic muscarinic receptors and decreases the heart rate. Another study revealed that somina also decreases the blood pressure (rats) by stimulating the muscarinic receptor. Present study confirmed that somina possess muscarinic receptor activity even when tested by using Langendorff heart assembly for rabbits. The partial agonist competing with the full agonist for receptor occupancy and producing a net decrease in the receptor activation observed with the full agonist alone [7]. Further the present study revealed that somina is a partial agonists (28% reduction in heart rate), somina bind to and activate receptor (muscarinic receptor), but have only partial efficacy at the receptor relative to a full agonist (Ach 10-3; 52% reduction). Further present study is in agreement with previous research that in the presence of a full agonist (Ach 10-3), a partial agonist Somina (20mg/ml) act as antagonist. In the present results the administration of combined therapy (Somina+Ach10-3), Somina competing with the full agonist (Ach 10-3) for the same receptor and thereby reducing the ability of the full agonist to produce its maximum effect (Ach 10-3 52%; Somina+Ach10-3 37% reduction) as shown in Figure 1. Clinically this research is very important,

  1. Partial agonists (somina) can be used to activate receptors (muscarinic) to give a desired sub-maximal response when small concentrations of the endogenous ligands (Ach) are present
  2. They (Somina) can reduce the overstimulation of receptors when excess amounts of the endogenous ligand (Ach) are present [8].


It is concluded that Somina (Herbal preparation) worked as partial agonist.


Authors are grateful to Prof. Dr SI Ahmed (Late), Former Dean Faculty of Pharmacy and Director DrHMIIPHS, Hamdard University Karachi for his support and encouragement at every stage of this study and also to Mr AQ Farooqi, Director, Quality Control Division, Hamdard Laboratories (Waqf), Karachi, Pakistan for the supply of drug samples and Hamdard Foundation for financial support.


  1. Kandangath RA, Ajay P, Farhath K, Amarinder SB (2010) Nutritional, Medicinal and Industrial, Uses of Sesame (Sesamum indicum L.) Seeds - An Overview. Agriculturae Conspectus Scientificus 75(4): 159-168.
  2. Fraser GE (1999) Nut consumption, lipids, and risk of a coronary event. Clin Cardiol 22(7 Suppl): III11- III15.
  3. Andrea H, Michaela H, Jana Š, Adriána B (2012) Poppy seed (Papaver Somniferum L): Effect of genotype and year of cultivation on variability in its lipid composition. J Microbiol Biotech Food Sci 1: 908-922.
  4. Janbaz KH, Latif MF, Saqib F, Imran I, Zia-Ul-Haq M, et al. (2013) Pharmacological Effects of Lactuca serriola L in Experimental Model of Gastrointestinal, Respiratory, and Vascular Ailments. Evid Based Complement Alternat Med 2013: 304394.
  5. Upaganlawar A, Balaraman R (2011) Cardioprotective Effects of Lagenaria siceraria Fruit Juice on Isoproterenolinduced Myocardial Infarction in Wistar Rats: A Biochemical and Histoarchitecture Study. J Young Pharm 3(4): 297-303.
  6. Atanasov AG, Wang JN, Gu SP, Bu J, Kramer MP, et al.(2013) Honokiol: A non-adipogenic PPARγ agonist from nature. Biochim Biophys Acta 1830(10): 4813-4819.
  7. Calvey N, Williams N (2009) Partial agonists. Principles and Practice of Pharmacology for Anaesthetists. p. 62. 
  8. Zhu, BT (2005) Mechanistic explanation for the unique pharmacologic properties of receptor partial agonists. Biomed Pharmacother 59(3): 76-89. 
© 2014-2018 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy